Phase 1 PROM Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
SarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaNeurofibroma, Plexiform+1 more
National Cancer Institute (NCI)54 enrolled1 locationNCT02390752
Recruiting
Phase 1
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute Promyelocytic Leukemia With PML-RARA
M.D. Anderson Cancer Center77 enrolled1 locationNCT02390635
Recruiting
Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Hematopoietic and Lymphoid Cell NeoplasmImmunocompromised
M.D. Anderson Cancer Center16 enrolled1 locationNCT03425526
Completed
Phase 1
A randomised, open label study to compare the bioavailability of 12mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules against the innovator 10mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules conducted under fasting condition in healthy male volunteers.
Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARa gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin is for the induction of remission only.
Zenith Technology Corporation Limited18 enrolled1 locationACTRN12620000287932
Completed
Phase 1
A Phase I, Randomised, Open Label Study of the Safety, Tolerability and Pharmacokinetics of Single Sublingual or Oral Dose of GDN-1 in Adult Healthy Volunteers.
This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.
Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.
Gordagen Pharmaceuticals Pty Ltd60 enrolled1 locationACTRN12615000560594
Completed
Phase 1
A Phase I, open label, randomised, single dose, two-way crossover study to determine the pharmacokinetics of two transdermal oxymorphone patch formulations.
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited15 enrolled1 locationACTRN12614000613606
Completed
Phase 1
An open label, phase I study to determine the pharmacokinetic, safety and tolerability profiles of oxymorphone delivered from multiple applications of a transdermal oxymorphone patch.
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited12 enrolled1 locationACTRN12613000932763
Completed
Phase 1
An open label, phase I single application study to determine the pharmacokinetic, safety and tolerability profiles of oxycodone delivered from a transdermal oxycodone patch.
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited12 enrolled1 locationACTRN12613000398707
Completed
Phase 1
An open label, single dose, phase I pilot study to determine the pharmacokinetic, safety and tolerability profiles of oxymorphone delivered from a transdermal oxymorphone patch
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited12 enrolled1 locationACTRN12613000085774
Completed
Phase 1
A single and repeat patch application study to determine what the body does to oxycodone in combination with tocopheryl phosphate mix, when delivered through the skin using a patch.
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited65 enrolled1 locationACTRN12612000059864
Completed
Phase 1
High-dose lenalidomide maintenance therapy in adult acute myeloid leukaemia (AML)
Newly diagnosed acute myeloid leukaemia (except Acute promyelocytic leukaemia (APML))
Australasian Leukaemia and Lymphoma Group (ALLG)50 enrolled1 locationACTRN12610000627055
Completed
Phase 1
A repeat patch application study to determine what the body does to oxycodone in combination with tocopheryl phosphate mix, when delivered through the skin using different methods of repeat application.
To promote pain relief, tested in healthy volunteers.
Phosphagenics Limited40 enrolled1 locationACTRN12610000514000
Completed
Phase 1
A phase I study to determine the tolerability and safety of transdermally delivered oxycodone in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM).
To promote pain relief in healthy volunteers.
Phosphagenics Limited44 enrolled1 locationACTRN12609000836235